The company will utilise this facility to commercialise non-invasive diabetes tests
DiabetOmics, a global medical diagnostics company that is developing the non-invasive, saliva-based diabetes monitoring test has opened its first manufacturing facility in Hyderabad. KT Rama Rao, Minster for IT, Municipal Administration & Urban Development, Industries & Commerce, Public Enterprises, inaugurated the facility recently. DiabetOmics will utilise this facility to commercialise their bluetooth-enablend nond a-invasive diabetes point of care (POC) tests and maternal health tests in India and around the world. Ventureast invested about 4 million in DiabetOmics in 2015.
This new facility, which is situated in a three acre plot in Muppireddipally will directly employ about 100-120 people. The overall capacity of the plant will be to produce 8-10 million test strips a year and 10,000 to 15,000 assembled readers to begin with. The company has completed construction of their manufacturing plant and the technology transfer from the US. The commercial production is expected to begin in the next quarter this year and will target the Indian and European markets.
Dr. Srinivasa Nagalla, CEO of DiabetOmics, said “We are pleased to bring these innovative diagnostic tests to the market beginning later part of this year which will be a huge paradigm shift for the patients around the world particularly for emerging countries like India where the affordability of quality care is a major burden for many low income families.”
Venkatadri Bobba, Director, DiabetOmics & General Partner, Ventureast said, “DiabetOmics has come a long way from the discovery of the Salivary Glycoproteins as the best biomarkers for Glycemic Index to product and Bluetooth-enabled readers. The new plant will be in full compliance with global regulatory requirements and will showcase high quality and low cost manufacturing capabilities of our highly qualified & well trained staff and the ecosystem enabled by the State of Telangana. Most importantly, it is gratifying to note that many patients and their families could benefit from our innovations beginning later part of this year.”